Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Januar 2023 06:30 ET | Quelle: Future Market Insights Global and Consulting Pvt. Ltd.

Global Alpha-1 Antitrypsin Deficiency (A1ATD) Treatment Market to Reach US$ 10 Billion by 2033; Growing at an Impressive 12.8% CAGR – Future Market Insights, Inc.

NEWARK, Del, Jan. 09, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Alpha-1 Antitrypsin Deficiency market to augment at a 12.8% CAGR from 2023 to 2033. By the end of...
20. Oktober 2021 07:30 ET | Quelle: Intellia Therapeutics, Inc.

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a...
27. April 2021 16:35 ET | Quelle: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) --...
12. Dezember 2020 09:00 ET | Quelle: Intellia Therapeutics, Inc.

Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy Single-course administration of genome editing system...